Charles Zhu
Stock Analyst at Guggenheim
(2.71)
# 1,853
Out of 5,182 analysts
19
Total ratings
52.94%
Success rate
27.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $23.02 | -47.87% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $18.76 | +17.27% | 1 | Jun 18, 2025 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $3.00 | +300.00% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $105.28 | -46.81% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.27 | +317.46% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $34.74 | -25.16% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $28.32 | +12.99% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $23.89 | -41.40% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $23.02
Upside: -47.87%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $18.76
Upside: +17.27%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $3.00
Upside: +300.00%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $105.28
Upside: -46.81%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.27
Upside: +317.46%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $34.74
Upside: -25.16%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $28.32
Upside: +12.99%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $23.89
Upside: -41.40%